Mirum's brelovitug meets Phase 3 primary endpoint in hepatitis delta trial

September 28, 2026 8:00 AM

Mirum Pharmaceuticals (NASDAQ: MIRM) announced that its investigational drug brelovitug met the primary endpoint in the Phase 3 portion of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found